Viking Therapeutics, Inc. (VKTX) Income Statement
VKTX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsVKTX revenue and net income
VKTX profit margins
VKTX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
VKTX quarterly EPS vs estimates
Viking Therapeutics beat the analyst EPS estimate in 2 of the last 8 quarters. Next report: October 28, 2026 (estimate $1.00).
VKTX income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $10,701 | $10,731 | $0 | $0 | $0 | $0 |
| Cost of revenue | $431,000 | $346,000 | $292,000 | $291,000 | $296,000 | $277,000 | $260,000 | $0 | $0 | $0 |
| Gross profit | −$431,000 | −$346,000 | −$292,000 | −$291,000 | −$296,000 | $10,731 | −$260,000 | $0 | $0 | $0 |
| Research & development | $345.0M | $101.6M | $63.8M | $54.2M | $45.0M | $31.9M | $23.6M | $19.0M | $13.7M | $9.0M |
| Sales, general & admin | $48.4M | $49.3M | $37.3M | $16.1M | $10.7M | $10.7M | $9.1M | $7.1M | $5.3M | $4.8M |
| Total operating expenses | $393.3M | $150.9M | $100.8M | $70.4M | $55.7M | $42.7M | $32.4M | $26.2M | $19.1M | $13.8M |
| Operating income | −$393.3M | −$150.9M | −$100.8M | −$70.4M | −$55.7M | −$42.7M | −$32.7M | −$26.2M | −$19.1M | −$13.8M |
| Interest income | $33.7M | $40.9M | $11.0M | $1.6M | $703,000 | $3.2M | $7.0M | $3.2M | $1,271 | $1.9M |
| Interest expense | $56,000 | $94,000 | $88,000 | $59,000 | $18,000 | $106,000 | $146,000 | $562,000 | $2.0M | $2.0M |
| Income before taxes | −$359.6M | −$110.0M | −$85.9M | −$68.9M | −$55.0M | −$39.5M | −$25.8M | −$22.1M | −$20.6M | −$14.7M |
| Income taxes | — | −$110.0M | −$292,000 | −$1.5M | −$988,000 | −$3.5M | $7.0M | −$2.7M | $1.9M | $1.9M |
| Net income | −$359.6M | −$110.0M | −$85.9M | −$68.9M | −$55.0M | −$39.5M | −$25.8M | −$22.1M | −$20.6M | −$14.7M |
| EBITDA | −$359.2M | −$109.5M | −$100.8M | −$68.5M | −$54.7M | $3.8M | −$25.4M | $4.7M | $442,882 | −$10.8M |
| EPS (diluted) | −$3.18 | −$1.00 | −$0.92 | −$0.91 | −$0.72 | −$0.54 | −$0.36 | −$0.39 | −$0.80 | −$1.00 |
| Gross margin | — | — | — | — | −2,766.1% | 100.0% | — | — | — | — |
| Operating margin | — | — | — | — | −520,343.9% | −397,558.5% | — | — | — | — |
| Net margin | — | — | — | — | −513,877.2% | −368,045.8% | — | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $436,000 | $0 |
| Cost of revenue | — | — | $94,000 | $114,000 | $112,000 | — | $110,000 | $87,000 | $75,000 | $74,000 | $74,000 | $73,000 |
| Gross profit | — | — | −$94,000 | −$114,000 | −$112,000 | — | −$110,000 | −$87,000 | −$75,000 | −$74,000 | −$74,000 | −$73,000 |
| Research & development | $115.8M | $150.2M | $153.5M | $90.0M | $60.2M | $41.4M | $31.0M | $22.8M | $23.8M | $24.1M | $20.5M | $18.4M |
| Sales, general & admin | $16.8M | $14.0M | $11.3M | $8.6M | $14.4M | $14.1M | $15.3M | $13.8M | $10.4M | $10.0M | $8.8M | $8.9M |
| Total operating expenses | $132.6M | $164.1M | $164.7M | $98.6M | $74.6M | $55.5M | $46.2M | $36.6M | $34.1M | $34.1M | $29.3M | $27.3M |
| Operating income | −$132.6M | −$164.1M | −$164.7M | −$98.6M | −$74.6M | −$55.5M | −$46.2M | −$36.6M | −$34.1M | −$34.1M | −$29.3M | −$27.3M |
| Interest income | $4.5M | $5.8M | $7.0M | $7.8M | $9.0M | $9.9M | $10.8M | $11.5M | $11.8M | $6.7M | $4.7M | $4.7M |
| Interest expense | — | — | — | $8,000 | $24,000 | $24,000 | $24,000 | $24,000 | $18,000 | $28,000 | $26,000 | $2,000 |
| Income before taxes | −$128.0M | −$158.3M | −$157.7M | −$90.8M | −$65.6M | −$45.6M | −$35.4M | −$24.9M | −$22.2M | −$27.4M | −$24.6M | −$22.5M |
| Income taxes | — | — | — | — | — | — | — | −$87,000 | — | $30,724 | $1.2M | −$73,000 |
| Net income | −$128.0M | −$158.3M | −$157.7M | −$90.8M | −$65.6M | −$45.6M | −$35.4M | −$24.9M | −$22.2M | −$27.4M | −$24.6M | −$22.5M |
| EBITDA | −$127.9M | −$158.2M | −$157.6M | −$90.7M | −$65.4M | −$45.5M | −$35.3M | −$24.8M | −$22.2M | −$27.3M | −$24.5M | −$22.5M |
| EPS (diluted) | −$1.10 | −$1.37 | −$1.38 | −$0.81 | −$0.58 | −$0.41 | −$0.32 | −$0.22 | −$0.20 | −$0.26 | −$0.25 | −$0.23 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | −17.0% | — |
| Operating margin | — | — | — | — | — | — | — | — | — | — | −6,716.7% | — |
| Net margin | — | — | — | — | — | — | — | — | — | — | −5,643.3% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in VKTX's financial statements (latest annual report filed February 11, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
VKTX financial results
Viking Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $359.6 million. Diluted earnings per share came to −$3.18.
See the VKTX stock overview for the latest quote and news, or the VKTX chart for price history and technical indicators.
VKTX income statement FAQ
Does Viking Therapeutics have revenue?
Viking Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Viking Therapeutics profitable?
No. Viking Therapeutics reported a net loss of $359.6 million in fiscal 2025.
How much does Viking Therapeutics spend on research and development?
Viking Therapeutics spent $345.0 million on research and development in fiscal 2025.
What are Viking Therapeutics's earnings per share?
Viking Therapeutics earned $-3.18 per diluted share in fiscal 2025, compared with $-1.00 a year earlier.
When will Viking Therapeutics report its next earnings?
Viking Therapeutics is expected to report results for the quarter ending September 30, 2026 on October 28, 2026 after the market closes.
When does Viking Therapeutics's fiscal year end?
Viking Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 11, 2026.